1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
6556.29%
Cash & equivalents growing 6556.29% while Drug Manufacturers - Specialty & Generic shows decline of -4.92%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
-100.00%
Short-term investments yoy growth below half the Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos would question if the firm lacks surplus cash or is facing liquidity stress.
4677.24%
Below half the Drug Manufacturers - Specialty & Generic median of -1.25% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
110905.89%
Receivables growth above 1.5x Drug Manufacturers - Specialty & Generic median of 2.08%. Jim Chanos might see a serious red flag in ballooning receivables.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5671.62%
Current assets growth ≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 1.00%. Joel Greenblatt sees a potential liquidity edge if well allocated.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7369.40%
≥ 1.5x the Drug Manufacturers - Specialty & Generic median of 1.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
2214.80%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 2.25%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2214.80%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 1.79%. Jim Chanos suspects an alarming rise in overall leverage.
5035.35%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-2598.80%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos suspects poor profitability or large dividend drains.
No Data
No Data available this quarter, please select a different quarter.
849113855.37%
Above 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
8437.09%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.65%. Joel Greenblatt sees stronger equity growth vs. peers.
7369.40%
≥ 1.5x Drug Manufacturers - Specialty & Generic median of 0.89%. Joel Greenblatt sees more aggressive expansions than peers.
-100.00%
Below half Drug Manufacturers - Specialty & Generic median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-6556.29%
Below half of Drug Manufacturers - Specialty & Generic median 4.53%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.
